MedPath

The Prolonged Effect of Consumption of a Partially Hydrolyzed Infant Formula During the First 6 Months of Life on the Development of Allergic Manifestations At 5 Years of Age

Completed
Conditions
Allergy
Interventions
Other: No intervention is used in the current study. Interventions were given in the original A.R.T. study
Registration Number
NCT05418491
Lead Sponsor
FrieslandCampina
Brief Summary

The present study is a 5-year follow-up of the Allergy Reduction Trial (A.R.T.) birth cohort study of 551 infants at high-risk for allergy. The A.R.T. 5-year follow-up study, aims to investigate the prolonged effect of each feeding regimen \[formula-fed (exclusively or partially) with the partially hydrolyzed formula (pHF) or the standard formula (SF), or exclusively breastfed\] within the first 6 months of life on the development of any allergic manifestations up to the age of 5 years. Allergic manifestations within this time period will include the presence of any of the following: atopic dermatitis, food allergies, respiratory allergies, urticaria, drug allergy and insect venom allergy. In addition, differences on growth (weight, height, BMI) will be examined.

Detailed Description

The present study is a 5-year follow-up of the Allergy Reduction Trial (A.R.T.) birth cohort study of 551 infants at high-risk for allergy. The A.R.T. 5-year follow-up study, aims to investigate the prolonged effect of each feeding regimen \[formula-fed (exclusively or partially) with the partially hydrolyzed formula (pHF) or the standard formula (SF), or exclusively breastfed\] within the first 6 months of life on the development of any allergic manifestations up to the age of 5 years. Allergic manifestations within this time period will include the presence of any of the following: atopic dermatitis, food allergies, respiratory allergies, urticaria, drug allergy and insect venom allergy. In addition, differences on growth (weight, height, BMI) will be examined.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
455
Inclusion Criteria
  • Children who were part of the Intention-to-Treat population of the A.R.T. study
  • Children of the A.R.T. study ITT population within the age range of 5 years up to 5 years and 3 months
  • Children of the A.R.T. study ITT population in whom at least one parent and/or legal guardian signed the written consent form
Exclusion Criteria
  • Children who did not participate in the A.R.T. study or who were not assigned to any of the 3 study arms
  • Children of the A.R.T. study who are younger than 5 years of age or older than 5 years and 3 months of age
  • Children of the A.R.T. study in whom parents and/or guardians do not agree to provide a written consent form

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Partially hydrolyzed protein Infant formulaNo intervention is used in the current study. Interventions were given in the original A.R.T. studyOriginating from A.R.T. cohort.
Standard infant formulaNo intervention is used in the current study. Interventions were given in the original A.R.T. studyOriginating from A.R.T. cohort.
Exclusively breastfed infantsNo intervention is used in the current study. Interventions were given in the original A.R.T. studyOriginating from A.R.T. cohort.
Primary Outcome Measures
NameTimeMethod
Incidence of allergic ManifestationsAt 5 years of age

Incidence of allergic manifestations (AM) based on parental reporting using Childhood Allergy questionnaire comparing partially hydrolyzed protein formula, standard formula and exclusive breastfeeding.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Medical University of Varna

🇧🇬

Varna, Bulgaria

Harokopio University

🇬🇷

Athens, Greece

Asthma and Allergy Centre LTD

🇨🇾

Limassol, Cyprus

© Copyright 2025. All Rights Reserved by MedPath